-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Adverum Biotechnologies (NASDAQ:ADVM) Stock Crosses Below Fifty Day Moving Average of $1.35
Adverum Biotechnologies (NASDAQ:ADVM) Stock Crosses Below Fifty Day Moving Average of $1.35
Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Rating)'s stock price passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.35 and traded as low as $1.02. Adverum Biotechnologies shares last traded at $1.02, with a volume of 477,944 shares traded.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on ADVM shares. StockNews.com lowered Adverum Biotechnologies from a "hold" rating to a "sell" rating in a research note on Wednesday, August 3rd. Truist Financial raised Adverum Biotechnologies from a "hold" rating to a "buy" rating and boosted their price target for the stock from $3.00 to $4.00 in a research note on Thursday, July 7th. Finally, Chardan Capital reduced their target price on Adverum Biotechnologies from $3.00 to $2.50 and set a "neutral" rating on the stock in a research note on Friday, August 12th.
Get Adverum Biotechnologies alerts:Adverum Biotechnologies Trading Down 3.3 %
The business has a 50 day moving average of $1.35 and a 200-day moving average of $1.21. The stock has a market cap of $100.75 million, a PE ratio of -0.65 and a beta of 1.14.
Adverum Biotechnologies (NASDAQ:ADVM – Get Rating) last posted its earnings results on Thursday, August 11th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.06). On average, equities research analysts anticipate that Adverum Biotechnologies, Inc. will post -1.5 EPS for the current fiscal year.Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of ADVM. Millennium Management LLC acquired a new position in Adverum Biotechnologies in the 2nd quarter valued at $1,246,000. Renaissance Technologies LLC raised its holdings in Adverum Biotechnologies by 175.7% in the 2nd quarter. Renaissance Technologies LLC now owns 1,093,041 shares of the biotechnology company's stock valued at $1,312,000 after acquiring an additional 696,600 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in Adverum Biotechnologies by 125.8% in the 1st quarter. Assenagon Asset Management S.A. now owns 992,729 shares of the biotechnology company's stock valued at $1,300,000 after acquiring an additional 553,155 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Adverum Biotechnologies in the 4th quarter valued at $919,000. Finally, Monaco Asset Management SAM acquired a new position in Adverum Biotechnologies in the 2nd quarter valued at $536,000. 64.26% of the stock is currently owned by institutional investors and hedge funds.
About Adverum Biotechnologies
(Get Rating)
Adverum Biotechnologies, Inc, a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema.
Read More
- Get a free copy of the StockNews.com research report on Adverum Biotechnologies (ADVM)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Rating)'s stock price passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.35 and traded as low as $1.02. Adverum Biotechnologies shares last traded at $1.02, with a volume of 477,944 shares traded.
在周二的交易中,Adverum BioTechnologies,Inc.(纳斯达克代码:ADVM-GET Rating)的股价跌破了50日移动均线。该股的50日移动均线切入位为1.35美元,最低交易价格为1.02美元。Adverum BioTechnologies的股票最新报1.02美元,成交量为477,944股。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Several equities research analysts have recently commented on ADVM shares. StockNews.com lowered Adverum Biotechnologies from a "hold" rating to a "sell" rating in a research note on Wednesday, August 3rd. Truist Financial raised Adverum Biotechnologies from a "hold" rating to a "buy" rating and boosted their price target for the stock from $3.00 to $4.00 in a research note on Thursday, July 7th. Finally, Chardan Capital reduced their target price on Adverum Biotechnologies from $3.00 to $2.50 and set a "neutral" rating on the stock in a research note on Friday, August 12th.
几位股票研究分析师最近对ADVM的股票发表了评论。在8月3日星期三的一份研究报告中,StockNews.com将Adverum BioTechnologies的评级从持有下调至卖出。7月7日,在一份研究报告中,Truist Financial将Adverum BioTechnologies的评级从持有上调至买入,并将该股的目标价从3.00美元上调至4.00美元。最后,Chardan Capital将Adverum BioTechnologies的目标价从3.00美元下调至2.50美元,并在8月12日(星期五)的一份研究报告中对该股设定了中性评级。
Adverum Biotechnologies Trading Down 3.3 %
Adverum BioTechnologies股价下跌3.3%
The business has a 50 day moving average of $1.35 and a 200-day moving average of $1.21. The stock has a market cap of $100.75 million, a PE ratio of -0.65 and a beta of 1.14.
该业务的50日移动均线切入位在1.35美元,200日移动均线切入位在1.21美元。该股市值为1.075亿美元,市盈率为-0.65,贝塔系数为1.14。
Institutional Inflows and Outflows
机构资金流入和流出
Several institutional investors have recently bought and sold shares of ADVM. Millennium Management LLC acquired a new position in Adverum Biotechnologies in the 2nd quarter valued at $1,246,000. Renaissance Technologies LLC raised its holdings in Adverum Biotechnologies by 175.7% in the 2nd quarter. Renaissance Technologies LLC now owns 1,093,041 shares of the biotechnology company's stock valued at $1,312,000 after acquiring an additional 696,600 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in Adverum Biotechnologies by 125.8% in the 1st quarter. Assenagon Asset Management S.A. now owns 992,729 shares of the biotechnology company's stock valued at $1,300,000 after acquiring an additional 553,155 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Adverum Biotechnologies in the 4th quarter valued at $919,000. Finally, Monaco Asset Management SAM acquired a new position in Adverum Biotechnologies in the 2nd quarter valued at $536,000. 64.26% of the stock is currently owned by institutional investors and hedge funds.
几家机构投资者最近买卖了ADVM的股票。千禧管理公司在第二季度收购了Adverum BioTechnologies的一个新头寸,价值1,246,000美元。复兴科技有限责任公司在第二季度增持了175.7%的Adverum BioTechnologies股份。复兴科技有限责任公司现在拥有这家生物技术公司1,093,041股股票,价值1,312,000美元,在上个季度增持了696,600股。Assenagon Asset Management S.A.在第一季度增持了125.8%的Adverum BioTechnologies股份。Assenagon Asset Management S.A.在上个季度增持了553,155股后,现在持有这家生物技术公司992,729股股票,价值130万美元。GSA Capital Partners LLP在第四季度收购了Adverum BioTechnologies的一个新头寸,价值91.9万美元。最后,摩纳哥资产管理公司SAM在第二季度收购了Adverum BioTechnologies的一个新头寸,价值53.6万美元。64.26%的股票目前由机构投资者和对冲基金持有。
About Adverum Biotechnologies
关于Adverum生物技术公司
(Get Rating)
(获取评级)
Adverum Biotechnologies, Inc, a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema.
Adverum BioTechnologies,Inc.是一家临床阶段的基因治疗公司,开发用于治疗眼科和罕见疾病的候选基因治疗产品。它的主要候选产品是ADVM-022,这是一种单一玻璃体内注射基因治疗候选药物,用于治疗慢性视网膜患者,包括湿性老年性黄斑变性和糖尿病黄斑水肿。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Adverum Biotechnologies (ADVM)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
- 免费获取StockNews.com关于Adverum BioTechnologies(ADVM)的研究报告
- 3家航空公司股票陷入持有格局
- Roku股票下跌,但并未出局
- 如果你渴望价值,那就尝尝露丝的好客之道吧
- 福特在第三季度发出警告后是否正在反弹
- AMD股票是不是跌得太厉害了?
Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受Adverum BioTechnologies Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Adverum BioTechnologies和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧